Czechia· CZ-0243197
BUSCOPAN
A butylscopolamine product containing hyoscine butylbromide, registered in Czechia by Mayoly Pharma France, Rueil-Malmaison. The same ATC class is registered in 11 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Butylscopolamine is registered in 11 of 19 countries.
Countries holding a registration under ATC A03BB01 (butylscopolamine), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 6 of them publish a price we can compare per daily dose
Butylscopolamine · ATC A03BB01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- HYOSCINE BUTYLBROMIDE
- Manufacturer
- Mayoly Pharma France, Rueil-Malmaison
- Country
- Czechia (CZ)
- ATC code
- A03BB01
- ATC class
- Butylscopolamine
- Defined daily dose
- 60 mg, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02431975X1MLCZK 158.33
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Butylscopolamine in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenBumacor 20 mg/ml Injektionsvätska, lösningMACURE PHARMA ApS
- NorwayBumacorMacure Pharma ApS
- BelgiumBuscopan 20 mg/mlOpella Healthcare Belgium
- NetherlandsBuscopan, injectievloeistof 20 mg/mlMedcor Pharmaceuticals B.V.
- United KingdomBuscopan 10mg tabletsDowelhurst Ltd
- FinlandBumacorMacure Pharma ApS
- GermanyBuscopanA. Nattermann & Cie. Gmbh
- CanadaACCEL-HYOSCINEACCEL PHARMA INC
Authorised across Europe · EMA
The same active substance is authorised in 27 EEA countries. Names it is sold under:
- Austria · Buscapina, Buscopan
- Belgium · Buscopan, Buscopan Forte
- Bulgaria · Бусколизин, Бусколизин Форте
- Cyprus · Avotrin, Buscopan
- Germany · Buscopan, Buscopan Ampullen
- Denmark · Bumacor
- Estonia · Bysimin
- Spain · Buscapina, Buscopresc
- Finland · Bumacor, Buscopan
- France · Buscopan, Scoburen
- United Kingdom (Northern Ireland) · Almus Ibs Relief, Almus Stomach Cramp Relief
- Greece · Avotrin, Buscopan
- Croatia · Buscopan, Bysimin
- Hungary · Buscopan, Buscopan Forte
- Ireland · Buscopan, Buscopan Ampoules
- Italy · Addofix, Buscopan
- Luxembourg · Buscopan, Buscopan Forte
- Latvia · Buscopan, Hyoscine Butylbromide Kalceks
- Malta · Buscopan, Buscopan Ampoules
- Netherlands · Buscopan, Scopolamine Butylbromide Kalceks
- Norway · Bumacor, Buscopan
- Poland · Aurogastro, Buscolysin
- Portugal · Buscopan, Butilescopolamina Conforpam
- Romania · Buscopan, Buscotil
- Sweden · Bumacor, Buscopan
- Slovenia · Buscopan
- Slovakia · Buscopan, Scopolamine Butylbromide Kalceks
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0a58e2c4-ec95-412b-a77d-13e21ea77255 GET /v1/drugs/0a58e2c4-ec95-412b-a77d-13e21ea77255?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ SOL",
"source": "sukl",
"strength": "20MG/ML",
"pack_size": "5X1ML",
"substance": "HYOSCINE BUTYLBROMIDE",
"cz_kod_sukl": "0243197",
"product_type": "CH",
"substance_codes": "753",
"registration_state": "R",
"registration_number": "73/009/71-S/C"
}See everything about butylscopolamine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.